Delivery Order SPE2DB22D1106-SPE2DB24FFFG1

Award Date 8/2/24
Potential Completion Date 8/5/24
Potential Value $9.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) has awarded a firm-fixed-price delivery order contract valued at $1,210.55 to AmerisourceBergen Drug Corp for the supply of 4,566,110,813 units of the prescription drug Vyvanse 40 mg capsules. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that the DLA Troop Support Medical has with AmerisourceBergen, valued at up to $999,999,999 through December 2025, for a comprehensive range of medical commodities to support military...
The U.S. Defense Logistics Agency (DLA) awarded a $1,681.65 firm fixed price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division. The contract is for the supply of 4,565,377,092 Vyvanse 40 mg capsules in 100-count bottles. This order falls under Amerisourcebergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for providing a comprehensive range of pharmaceutical and medical supplies to...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $2,799.28 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,565,763,686 units of Vyvanse 30 mg capsules. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for providing a comprehensive range of medical commodities to support...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $10,838.56 to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of 4,564,734,299 units of the prescription medication Vyvanse (60mg capsules) over a period ending on May 30, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical, serving as the primary vehicle for the company to...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $2,986.64 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,566,198,098 units of the medication Vyvanse 40 mg capsules. The contract has a firm fixed-price pricing type and an ultimate completion date of October 25, 2024. This award is a task order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
The U.S. Defense Logistics Agency (DLA) awarded a $4,082.52 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide 4,565,752,660 units of the drug Vyvanse 10 mg capsules. This contract has an ultimate completion date of September 11, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which serves as the primary...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4,564,196,506 units of Vyvanse 40 mg capsules. The $2,240.98 contract has an ultimate completion date of April 8, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, valued at up to $999,999,999.00 through December 31, 2025. The IDC serves...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation, to provide 4,563,982,056 units of the drug Vyvanse 50 mg capsules. The $1,741.36 contract has a performance period through March 18, 2024 and does not utilize any set-aside designations. This delivery order is issued under a larger indefinite delivery contract (IDC) with a potential value of...
The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract valued at $10,833.45 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,559,778,029 units of Vyvanse 30 mg capsules. The contract has a firm fixed price and an ultimate completion date of January 31, 2023. This award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999 through November 2026, which...
The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division for the supply of 4,564,933,271 units of the prescription drug Vyvanse 30 mg capsules. The $1,374.00 firm-fixed-price contract has a completion date of June 18, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. Under this IDC,...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB24FFFG1
    Delivery Order

The Defense Logistics Agency (DLA) has awarded a $9,524.76 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division, a major pharmaceutical distributor, for the supply of 4,565,333,941 units of the prescription drug Vyvanse 40 mg capsules. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical for providing a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract has a performance period through August 5, 2024 and does not utilize a set-aside designation.

Generated 11/1/24, 9:03 AM